Abstract
Total joint replacement has been one of the most remarkable successes of modern medical technology. Once John Charnley had solved the problems of implant design, choice of materials, implant fixation, and infection (initial rates of infection were approximately 10%), the way was clear for the widespread use of this valuable treatment, which is highly effective at removing pain and restoring function. Unfortunately, infection still remains an important, though less common, problem. It is associated with serious morbidity (pain, loss of function, wound breakdown, wound discharge, implant failure) and sometimes mortality. It may be impossible to eradicate or suppress infection in the long term without removal of the prosthesis, and most clinicians would consider it unwise to re-implant a new prosthesis in the presence of infection. Hence, patients with infected prosthetic joints generally require multiple additional operations and prolonged periods of antibiotic therapy. Even radical attempts at cure may fail (in 10% to 15% of cases in most series), requiring further cycles of treatment with progressively deteriorating function. Thus, the treatment of prosthetic joint infection is arduous for the patient and the health care team, with no guarantee of success.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Berbari EF, Hanssen AD, Duffy MC, et al.: Risk factors for prosthetic joint infection: case control study. Clin Infect Dis 1998, 27:1247–1254. This paper studied risk factors for infection in a case-control design from a population of 26,505 patients undergoing total joint replacement. A definitive contribution.
Foster TJ, McDevitt D: Molecular basis of adherence of staphylococci to biomaterials. In Infections Associated with Indwelling Medical Devices. Edited by Bison AL, Waldvogel FA. Washington, DC: ASM Press; 1994.
Costerton JW, Lewandowski Z, Caldwell DE, et al.: Microbial biofilms. In Annual Review of Microbiology, volume 49. Edited by Ornston LN, Barrows A, Greenberg EP. 1995:711–745.
McKenney D, Hubner J, Muller E, et al.: The ica locus of Staphylococcus epidermidis encodes production of the capsular polysaccaride/adhesin. Infect Immun 1998, 66:4711–4720. Useful clarification that two apparently distinct adhesins are made by the same locus.
Pratt LA, Kolter R: Genetic analysis of Escherichia coli biofilm formation: roles of flagella, motility, chemotaxis and type I pili. Mol Microbiol 1998, 30:285–293. This paper, like the one by O’Toole and Kolter [6••], convincingly shows that bacterial motility is important in establishing the sessile state!.
O’Toole GA, Kolter R: Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 1998, 30:295–304. This paper, like the one by Pratt and Kolter [5••], convincingly shows that bacterial motility is important in establishing the sessile state!.
Proctor RA, Kahi B, von Eiff C, et al.: Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Clin Infect Dis 1998, 27:S68-S74. Useful review of this phenomenon and its possible role in persistence.
Coulter SN, Schwan WR, Ng EYW, et al.: Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments. Mol Microbiol 1998, 30:393–404. Demonstrates the power of the signature-tagged mutagenesis approach developed by Dr. David Holden.
Hensel M, Shea JE, Gleeson C, et al.: Simultaneous identification of bacterial virulence genes by negative selection. Science 1995, 269:400–403.
Belmatoug N, Cremieux AC, Bleton R, et al.: A new model of experimental prosthetic joint infection due to methicillinresistant Staphylococcus aureus: a microbiologic, histopathologic and magnetic resonance imaging characterization. J Infect Dis 1996, 174:313–317.
Maloney WJ, Jasty M, Harris W, et al.: Endosteal erosion in association with stable uncemented femoral components. J Bone Joint Surg Am 1990, 72-A:1025–1034.
Reddi K, Meghji S, Nair SP, et al.: The Escherichia coli chaperonin 60 (groEL) is a potent stimulator of osteoclast formation. J Bone Min Res 1998, 13:1260–1266. Important advance in understanding the mechanisms of bone loss in infection.
Meghji S, Crean SJ, Hill PA, et al.: Surface-associated protein from Staphylococcus aureus fstimulates osteoclastogenesis: possible role in S. aureus-induced bone pathology. Br J Rheum 1998, 37:1095–1101. Pursues the same line of inquiry as Reddi et al. [12••]. Important study, though more preliminary.
Tunney MM, Patrick S, Gorman SP, et al.: Improved detection of infection in hip replacements: a currently underestimated problem. J Bone Joint Surg Br 1998, 80-B:568–572. A novel approach to isolating pathogens in prosthetic joint infection that is awaiting evaluation against a clear criterion standard of infection.
Atkins BA, Athanasou N, Deeks J, et al.: Prospective evaluation of microbiological criteria for diagnosing infection at revision arthroplasty. J Clin Microbiol 1998, 36:2932–2939. A major prospective study attempting to establish robust microbiologic criteria for diagnosing prosthetic joint infection. Now awaits validation.
Powles JW, Spencer RF, Lovering AM: Gentamicin release from old cement during revision hip arthroplasty. J Bone Joint Surg Br 1998, 80-B:607–610. An important cautionary tale.
Brandt CM, Sistrunk WW, Duffy MC, et al.: Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis 1997, 24:914–919. A well-executed study with Kaplan-Meier survival curves that shows the poor results of salvage of knee replacements infected with this pathogen.
Crockarell JR, Hanssen AD, Osmon DR, et al.: Treatment of infection with debridement and retention of the components following hip arthroplasty. J Bone Joint Surg Am 1998, 80-A:1306–1313. Further excellent study from the Mayo Clinic, but it does not detail antibiotic regimens.
Segreti J, Nelson JA, Trenholme GM: Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis 1998, 27:711–713. Suppressive therapy can work in the right circumstances, but these circumstances need defining.
Zimmerli W, Widmer AF, Blatter M, et al., for the Foreign-Body Infection (FBI) Study Group: Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA 1998, 279:1537–1541. An important paper that demonstrates that a proportion of infections can be arrested for long periods with good function using a quinolone-rifampin combination. Also demonstrates the evolution of ciprofloxacin resistance in staphylococci on continuous monotherapy.
Widmer AF, Frei R, Rajacic Z, et al.: Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990, 162:96–102.
Widmer A.F, Gachter A, Ochsner PE, et al.: Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis 1992, 14:1251–1253.
Drancourt M, Stein A, Argenson JN, et al.: Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected implants. Antimicrob Agents Chemother 1993, 37:1214–1218.
Buchholz HW, Elson RA, Engelbrecht E, et al.: Management of deep infection of total hip replacement. J Bone Joint Surg Br 1981, 63-B:342–353.
Raut VV, Siney PD, Wroblewski BM: One stage revision arthroplasty of the hip for deep gram negative infection. Int Orthop 1996, 20:12–14.
Ure KJ, Amstutz HC, Schmalzried TP: Direct-exchange arthroplasty for the treatment of infection after total hip replacement. J Bone Joint Surg Am 1998, 80-A:961–968. One-stage revision is not dead, and can still deliver good results in selected cases.
Duncan CP, Beauchamp C: A temporary antibiotic-loaded joint replacement system for management of complex infections involving the hip. Orthop Clin North Am 1993, 24:751–759.
Younger ASE, Duncan CP, Masri BA: Treatment of infection associated with segmental bone loss in the proximal part of the femur in two stages with use of an antibiotic-loaded interval prosthesis. J Bone Joint Surg Am 1998, 80-A:60–69. Further experiences of complex infections managed with PROSTALAC.
Wenzel RP, Edmond MB: Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin Infect Dis 1998, 27:245–251. A sensible and helpful article from one of the world leaders in hospital infection control.
Hiramatsu K: Vancomycin resistance in staphylococci. Drug Resist Update 1998, 1:135–150. A useful review from an authority in the field who was the first to identify vancomycin-resistant S. aureus.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berendt, A.R., McLardy-Smith, P. Prosthetic joint infection. Curr Infect Dis Rep 1, 267–272 (1999). https://doi.org/10.1007/s11908-999-0029-z
Issue Date:
DOI: https://doi.org/10.1007/s11908-999-0029-z